Experienced in Progressive Supranuclear Palsy Atypical

Terence J. O'brien

Level 6, 99 Commercial Road, 
Melbourne, VIC, AU 
Experienced in Progressive Supranuclear Palsy Atypical
Level 6, 99 Commercial Road, 
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Terence O'brien practices in Melbourne, Australia. Mr. O'brien is rated as an Experienced expert by MediFind in the treatment of Progressive Supranuclear Palsy Atypical. His top areas of expertise are Epilepsy, Seizures, Absence Seizure, and Generalized Tonic-Clonic Seizure.

His clinical research consists of co-authoring 660 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Progressive Supranuclear Palsy Atypical.

Gender
Male

Locations

Level 6, 99 Commercial Road, Melbourne, VIC 3004, Australia
Other Locations
Grattan Street, Parkville, VIC 3010, Australia
27 Rainforest Walk, Clayton, VIC 3800, Australia
Grattan Street, Parkville, VIC 3050, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
Enrollment Status: Terminated
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: CT1812
Study Phase: Phase 2
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drug: Soticlestat
Study Phase: Phase 3
Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study
Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Deferiprone
Study Phase: Phase 2
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: YKP3089
Study Phase: Phase 3
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 Via an Implantable Pump and a Cranial Port and Double Lumen Catheter (ICVRX) in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 Via an Implantable Pump and a Cranial Port and Double Lumen Catheter (ICVRX) in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Combination product
Study Drug: ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
Study Phase: Phase 2
Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Enrollment Status: Active_not_recruiting
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: BIS-001ER
Study Phase: Phase 1/Phase 2
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

660 Total Publications

Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues.
Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues.
Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. O'brien's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 13 Advanced Conditions
View All 48 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile